SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-055701
Filing Date
2024-05-08
Accepted
2024-05-08 16:17:51
Documents
76
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cere-20240331.htm   iXBRL 10-Q 2365750
2 EX-31.1 cere-ex31_1.htm EX-31.1 14480
3 EX-31.2 cere-ex31_2.htm EX-31.2 14475
4 EX-32.1 cere-ex32_1.htm EX-32.1 7877
5 EX-32.2 cere-ex32_2.htm EX-32.2 7884
6 GRAPHIC img33951065_0.jpg GRAPHIC 118846
  Complete submission text file 0000950170-24-055701.txt   9722026

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cere-20240331.xsd EX-101.SCH 1384990
79 EXTRACTED XBRL INSTANCE DOCUMENT cere-20240331_htm.xml XML 1624894
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39311 | Film No.: 24926359
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)